Introduction
For decades, culture of primary rodent neurons was the predominant cellular model system for mammalian neurobiology. The last few years have seen a widespread increase in the use of human neuronal systems. These efforts stem from the long-held promise that induced pluripotent stem cells (iPSC) (Takahashi et al., 2007; Yu et al., 2007) will deliver large and reproducible quantities of relevant human neural cells suitable to support the development of new therapies. This capability is expected to be game-changing for many neurological disorders burdened with poorly translatable preclinical animal models, limited access to viable human primary tissue, and high unmet medical need. Furthermore, human datasets that support the scientific rationale for new targets have become a prerequisite for any significant investment by biopharmaceutical companies, and relevant in vitro models are required to assess therapeutic properties of candidate drugs in a human cellular context. Precision medicine initiatives and changes in the drug regulatory landscape are providing additional impetus to develop solutions for use of highquality, patient-derived cells in a reproducible and controlled environment (Collins and Varmus, 2015) .
Obstacles to the use of iPSC-derived models are rapidly eroding. The availability of patient-derived iPSC lines resulting from US and European initiatives has made tools from government sponsored research available to more scientists and contributed to widespread use of iPSCs (De Sousa et al., 2017; Kim et al., 2017; Rao and Collins, 2012; Streeter et al., 2017) . The advent of CRISPR engineering of iPSCs enables researchers to make paired patient mutation lines and isogenic control lines (Chang et al., 2015; Flynn et al., 2015; Xie et al., 2014) . Additionally, CRISPR engineering has facilitated the generation of iPSC lines with fluorescent tags that delineate specific subcellular compartments, such as those in the Allen Cell Collection, or with reporters that indicate the activation of specific genes or pathways Roberts et al., 2017) . Single-cell RNA sequencing (scRNA-seq) combined with lineage tracing and computational analysis is rapidly expanding our understanding of developmental biology and allowing the generation of more specific and efficient iPSC-differentiation protocols (La Manno et al., 2016; Raj et al., 2018; Zhong et al., 2018) . Together, these advances have contributed to an increase in the use of iPSCderived neurons as an alternative to transformed cell lines and primary rodent neurons.
On the one hand, this welcome increase in the use of human iPSC-derived neurons is teaching us a great deal about how to work with these extraordinary cells. On the other hand, there is the potential to generate vast quantities of data based on artificial elements of the in vitro environment. Just because one can reproducibly detect a difference between a disease and control cell, whether it is an iPSC-derived cell or not, does not mean that it will be a valuable endpoint for determining therapeutic relevance or that molecules that reverse it will lead to clinical benefit. As is true of any screen, it takes careful inquiry to determine if a cellular phenotype is meaningful for unraveling an underlying biological mechanism or identifying therapies that will benefit patients. Translatability from the cell culture dish to the clinic cannot be assumed, even if the starting material is a biologically relevant, iPSC-derived terminal cell type generated from a patient. The current collective hypothesis in drug discovery is that in vitro cellular models that better represent the in vivo environment will lead to improved clinical predictability. Testing of this hypothesis is underway across a range of therapeutic indications, and in the field of neuroscience, iPSC-derived cells are often at the center of these studies.
To understand the state of the art as it relates to the use of iPSC-derived neural cells for what has been called translational disease modeling, we reviewed the literature and evaluated reports of screens involving more than 25 small molecule compounds that used stem-cell-derived neural progenitor cells (NPC) or neurons (listed in Table S1 ). We excluded reports related to the important use of iPSC-derived cells as direct therapies for treating neurological diseases (for example : Connor, 2018; Parmar, 2018) in order to focus on the use of iPSC-derived cells for in vitro disease modeling. We limited our assessment to small-molecule compound screens in NPCs or neurons, as these studies represented the majority of the reports. The intent was to allow us to better compare parameters of assay quality and translatability across a more similar collection of screens. The lower limit of 25 compounds was chosen to distinguish between screens that potentially could be used in a traditional highthroughput screen (HTS) to enable drug discovery from those with lower throughput that are more amenable to hypothesistesting assays. We evaluated these screens for a variety of parameters that reflect assay quality and translatability, as documented in Tables 1 and S2 . Quality was assessed based on the degree of cellular characterization, inclusion of assay controls, counter screens, and demonstration of reproducibility. For this analysis, ''translatability'' was defined by principles described by Vincent and colleagues for developing predictive phenotypic screens (Vincent et al., 2015) and included evaluation of the relevance of the cell type, stimulus, and endpoint with respect to the disease being modeled. This enabled a graphic comparison of the overall quality of published screens from the past 7 years, as shown in Figure 1 . We frequently found that descriptions provided by many of the reports lacked basic information required for evaluating the quality of the screen or enabling replication of the screen. Our results echo the findings of Hollingsworth and colleagues (Hollingsworth et al., 2017) , who performed a systematic evaluation of phenotype-genotype relationships in iPSC-derived models and noted heterogeneity in current research practices. The lack of technical detail and clear biological relevance was even true of some very recent screens, although there was a trend toward more complete information and greater cell-biological relevance, as evidenced by more screens from the last 4 years (shown in green bubbles) being positioned in the upper right-hand quadrant of Figure 1 . This trend most likely reflects a young field refining itself and better applying the attributes of iPSC-derived cells to disease model development.
In this primer, we provide a framework for considering the translatability of in vitro assay endpoints for disease modeling. Additionally, we offer technical guidance for working with iPSC-derived cells for higher throughput screening to ensure rigor and reproducibility. We highlight the potential for future use of three-dimensional (3D) systems to create more translatable platforms for disease modeling and examine some of the technical hurdles that remain.
Developing Translatable In Vitro Disease Models and Therapeutic Drug Discovery Screens
Historically, drug discovery, either serendipitous or purposeful, was driven by changes in phenotype (Ban, 2006) . For example, the anticonvulsant zonisamide was first discovered by routine testing of compounds in a rodent seizure model (Masuda et al., 1998) . Cell-based in vitro models and phenotypic screens have become more common in recent years. Critical to the success of phenotype-based screening is the ability of the model system to manifest the chosen phenotype. The emergence of reproducible protocols to differentiate human neurons from iPSCs has finally put the unique functional properties of neurons into the realm of observation for phenotypic screening.
Even the most ardent supporters of iPSCs acknowledge that these cells can be technically challenging to culture and differentiate. Furthermore, they are still more costly and labor-intensive to use than primary rodent neurons or immortalized cell lines. In theory, iPSC-derived cells can be employed in screens involving any type of modality, including small molecules, antibodies, or nucleic acids (anti-sense oligonucleotides, shRNAi, CRISPR). Careful consideration should be given to the design and validation of an iPSC-based model and/or screen to ensure that the additional cost and labor are justified by expected benefits gained by using the cells.
The best iPSC-based models and screens take advantage of unique properties of the differentiated cell type. In 2015, Vincent and colleagues laid out the ''phenotypic screening rule of 3'' as a guiding premise for evaluating the translational value of phenotypic screens. (Vincent et al., 2015) They proposed that the best phenotypic screens show (1) high disease relevance of the assay system, including use of the appropriate native cell type; (2) a disease relevant stimulus to produce the phenotype, such as an endogenous mutation; and (3) an assay readout that correlates with the clinical endpoint. This does not imply that iPSC-based models must be perfect replicas of in vivo biology; they need only capture the complexity of the in vivo phenotype to be studied (in other words, the assay is ''fit for purpose''). Direct measurement of disease-relevant proteins or functionally important changes in electrical properties of neurons are often the most relevant assay endpoints. Random introduction of truncated promoter-luciferase reporters or treatment of iPSC-derived cells with supraphysiological concentrations of a cytotoxin to induce a cellular phenotype will circumvent the advantages and decrease the translational value of the system. Weak, low-penetrant, or environmentally induced phenotypes may be difficult to measure robustly, and some phenotypes associated with late-onset disorders may not be revealed in the absence of conditions that induce cellular stress or aging. Capturing human disease relevance is the first step in defining a ''chain of translatability'' that links the mechanisms underlying the assay phenotype directly to the same molecular drivers found in the selected preclinical disease model and ultimately to the clinical features to be measured in patients (Moffat et al., 2017) . The strength of the chain of translatability defines the likelihood that a therapeutic drug discovery effort will yield meaningful results (Wehling, 2009; Wehling, 2012, 2017) . The strongest case for using an iPSC-based model is its presumed physiological relevance. The fundamental advantage of iPSC-derived cell types is that they can be human. This is particularly important in the field of neuroscience, in which increasing numbers of examples demonstrate that human neurons rely on species-specific genes and mechanisms (Hardingham et al., 2018; Hawrylycz et al., 2015; Khaitovich et al., 2004; Xu et al., 2016b) . Human primary neurons generally are not widely available, and never are in the quantities necessary to support screening for therapeutic drug discovery. Differentiated human iPSC routinely achieve gene expression signatures that squarely align the differentiated cells with many appropriate in vivo target brain cell types, although they fail to achieve all the appropriate hallmarks of a comparable, fully mature brain cell (Handel et al., 2016; Sloan et al., 2017; Yao et al., 2017) . Despite their immature phenotype, iPSC-derived neurons are capable of fundamental neuronal functions, including firing of action potentials and release of neurotransmitters (Bardy et al., 2016) . While the field will continue to strive for cell types that better match those found in vivo by incorporating an aging component (see below), an iPSC-derived neuron remains a better model of a terminally differentiated and native human neuron than immortalized or engineered cell lines. The ability to differentiate cells carrying specific mutations which are derived from a patient or that are CRISPR engineered makes it possible to directly evaluate the impact of disease-relevant mutations. These are the features that can make developing an iPSC-based screen worth the added effort and expense.
Technical Guidance for Working with Human iPSC-Derived Neural Cells for In Vitro Disease Modeling and Screening As mentioned above, our survey of the current iPSC-derived modeling and screening literature revealed that descriptions of many of the models and screens we reviewed lacked adequate technical information to replicate or evaluate the quality of the work. Given the complexity of working with iPSC-derived cells, this lack of information makes it difficult to interpret the significance of the results. We compiled a brief technical guide for best practices that can be considered and reported when performing iPSC-derived disease modeling and screening. While many of the suggestions represent best practices irrespective of the cell type, we have focused on potentially challenging issues associated with working with iPSC. A representative workflow built on best practices is found in a flowchart provided in Figure 2 , and an example of key descriptors that should be reported are listed in Figure 3 . The rationale for these recommendations is described in the following sections. iPSC Line Selection Cell-based in vitro disease modeling and assay development require high-quality cellular reagents to produce meaningful data. This starts with the generation or acquisition of the iPSC lines. The requirement that iPSC lines with published data be made available has facilitated access to and sharing of a greater pool of iPSC lines; however, it is worth noting that one consequence of the ''crowdsourcing'' of iPSC lines (Rao, 2013) is that iPSC lines with poor quality or minimal quality control characterization are often widely distributed. It is critical for investigators to know the history of lines that they receive from collaborators and to independently verify the quality and identity of lines upon receipt. Whenever possible, researchers should consider the use of iPSC lines that are available through stem cell banks that use good cell banking practices (Ntai et al., 2017; Stacey, 2012 ) (listed in Table 2 ) and provide basic quality documentation Literature reports of compound screens (> 25 compounds) between January 2012 and May 2018 were evaluated for criteria related to translatability (y axis) and assay quality (x axis). For translatability, three categories (the relevance of the cell type, the assay stimulus and the endpoint) were considered. For assay quality, five categories (iPSC characterization, terminal cell type characterization, assay controls, assay description, assay validation) were evaluated. Each category was evaluated on a scale of 1 to 5, with 1 being least relevant or well documented and 5 being most relevant or well documented. Supplemental material and references were consulted as necessary to determine if supporting data were available. Documented characterization of the samples described in the paper was considered to be of higher quality than referenced data. The number of compounds screened is indicated by the size of the bubble. The year in which the screen was published is indicated by the color of the bubble. A list of the papers and more information on the process used to evaluate them can be found in the supplemental information.
(see below). Alternatively, researchers have the option to document the generation and quality of their iPSC lines as a Lab Resource in a peer-reviewed publication (https://www.journals. elsevier.com/stem-cell-research/lab-resources). Standardized nomenclature (Kurtz et al., 2018; Luong et al., 2011) and the use of commonly available iPSC lines provides the added benefit of making it easier for other investigators to replicate key results and builds credibility.
A variety of variables can be considered when choosing iPSC lines to include in a study. For many years, technical issues such as the method of reprogramming or the initial somatic tissue source for reprogramming were considered significant sources of variation and thought to be important variables to control (Schlaeger et al., 2015; Thomas et al., 2015; Vitale et al., 2012; Vitaloni et al., 2014) . Numerous studies have since shown that the predominant source of variation in stably reprogrammed iPSC lines is a cell's genetic make-up (Burrows et al., 2016; D'Antonio et al., 2017; Kytt€ al€ a et al., 2016; Miyagishima et al., 2016; Nishino and Umezawa, 2016; Rouhani et al., 2014; Young et al., 2012) . This finding was recently confirmed by two largescale studies (DeBoever et al., 2017; Kilpinen et al., 2017) .
Given that genetic background drives variation, a significant range can exist for any phenotype. This necessitates evaluation of multiple control and patient iPSC lines to determine the full range of ''normal'' and the degree of separation between normal and the disease state. It is generally considered easier to study disease states caused by known genetic mutations as compared to idiopathic manifestations of the same disease; however, in either case, the overall genetic background can influence the expression of the phenotype. In the case of a known genetic mutation, genomic editing technologies can be used to correct the disease-causing mutation and create an isogenic control that will minimize variation and provide confidence that the observed phenotype is the result of the mutation. It is becoming standard practice to also introduce the genetic mutation into a control iPSC to evaluate the ability of the mutation to manifest the phenotype in ''non-permissive'' genetic background. When evaluating phenotypes in iPSC-derived cells that are derived from individuals with sporadic or polygenetic disease, it is not possible to apply genomic editing technologies to create appropriate controls; therefore, it is necessary to increase the number of iPSC lines evaluated. A study by Germain and Testa showed that, according to transcriptomic profiling of undifferentiated iPSCs, the use of more than one clone per individual in combination with standard analytical practices decreased specificity with marginal impact on sensitivity (Germain and Testa, 2017) . Their analysis further suggested that 3 to 4 pairs of isogenic clones or 4 to 6 individuals per group provided a reasonable balance of sensitivity and specificity. While the authors did not evaluate phenotypes in differentiated cells, they reasonably suggest that their analysis provides a baseline from which to start.
Another potential source of variation is the sex of the iPSC lines (Mekhoubad et al., 2012; Salomonis et al., 2016) . A study of 215 iPSC lines (55% female) showed considerable variation in the amount of X-chromosome reactivation in early passage (< 12) lines, and others have found that random X-chromosome inactivation is generally re-acquired with later passages (DeBoever et al., 2017) . This can be confounding, as it can impact differentiation potential as well as the allele being studied in X-linked diseases such as Fragile X and Rett syndromes. When female iPSC lines are used, they should be characterized for X-chromosome inactivation status and homogeneity. iPSC Culture Good cell culture practice (GCCP) must be rigorously enforced to maximize reproducibility and minimize artifacts. The Transatlantic Think Tank for Toxicology recently published detailed guidance on GCCP for stem cells and stem-cell-derived models Pamies and Hartung, 2017) . Six principles related to cell culture, reagent quality, documentation, safety, legal compliance, and training are described in detail. Appropriate training and legal compliance are largely assumed but should be noted. Documentation of tissue culture and reagent information can be easily collected in a single table to provide a foundation for establishing interpretation of an assay (Figure 3 ). Many journals now require this information as condition of publication, which should help establish these best practices (Han et al., 2017; Marcus, 2016) . Of particular importance are quality control parameters associated with undifferentiated iPSC culture (Keller et al., 2018) . iPSC lines are very sensitive to the stresses of cell culture and prone to genomic instability. Routine and rigorous characterization procedures are required at all stages. Morphology is an obvious indicator of iPSC health. At an operational level, researchers should be meticulous in their chosen method of culturing iPSC and become well trained to recognize the optimal morphology and proliferation characteristics of their specific iPSC lines. When physical signs of spontaneous differentiation are recognized, investigators must act-preferably by thawing a fresh vial of cells from a master bank or, in limited situations such as receiving or isolating new lines, manually removing areas of differentiation. Poor, intermittent, or chronic iPSC culture technique may have a cumulative effect on the quality of iPSC lines and their long-term differentiation capacity. GCCP cannot usually rescue a line once it has been inadequately handled for a prolonged period of time.
Depending upon the method used for iPSC reprogramming, iPSC lines should be used only after confirmation that the preprogramming factors have been eliminated (Schlaeger et al., 2015) . Karyotyping, pluripotency, and mycoplasma testing ought to be performed upon generation of a master stock of undifferentiated iPSCs (generally 10-20 vials) and again after each expansion needed to generate a working stock (generally 50-100 vials of cells). Genotyping should be performed on iPSC lines with known mutations when they are generated or received. Short tandem repeat (STR) PCR analysis should be performed on all lines upon receipt to set a baseline for authentication. Because of the known issues with genetic stability following prolonged continuous culture, undifferentiated iPSC lines ought to be maintained for only a limited number of passages (generally < 5) and routinely replaced with freshly thawed cells. These practices will reduce the likelihood of acquiring genetic changes such as p53 mutations or propagating issues arising from poor handling, such as mycoplasma contamination, or spontaneous differentiation that may cause drift in the culture phenotype (Merkle et al., 2017) . Array-comparative genome hybridization ought to be considered if the iPSC line will be genetically manipulated to ensure that the manipulation does not isolate a clone with a significant rearrangement, insertion, and/ or deletion not detectable by classical G banding (Yumlu et al., 2017) . Cell service providers, recognizing their role in ensuring high-quality results, are beginning to offer bundled services which provide the basic characterization of karyotype, pluripotency, and mycoplasma testing. The expense and labor associated with conducting quality control on iPSC lines prior to master banking often discourages investigators from fully evaluating these reagents before starting work, but the investment ensures development of a high-quality disease model.
Neural Differentiation
The first step in ensuring the quality of iPSC-derived neural cells is clear documentation of the protocol used to produce the cells. A variety of culture-driven protocols for neural differentiation have been published. Culture-driven protocols seek to recapitulate embryonic differentiation. Some protocols focus on the generation of a stable neural progenitor (NPC), while others focus on The increased use of human pluripotent stem-cell-derived cell types in compound and other types of screens requires the capture of information specific to stem cells that directly impacts the quality of the screens. Capture of this information in a systematic way would enable more transparent and accessible reporting of the information.
continuous differentiation to the terminal neural cell type, either of which may be appropriate depending upon the model under development. While many of these protocols start with the now-well-established principle of dual SMAD inhibition (Chambers et al., 2016) , subtle differences in the temporal addition or concentration of patterning factors can lead to remarkably different neural cell types; thus, it is essential for reproducibility to establish detailed work instructions. Documentation of the cell density and time in culture is also essential for reproducibility, as functional maturation has been shown to increase with time in culture (Berry et al., 2015; Odawara et al., 2016; Prè et al., 2014) . This should include time from initiation of differentiation or post-thaw of cryopreserved NPCs to time of use. Culture-driven protocols should be tested with multiple independent iPSC lines to ensure that the protocols are robust and will inform the amount of natural variation in cell type yield. When possible, highly variable cell-culture reagents (for example, serum, protein growth factors, extracted cellular matrices, etc.) should be eliminated or replaced with recombinant proteins or small molecules from reputable vendors to reduce variability. Scalability must also be assessed if the cells are to support larger-scale screening, as even moderately sized screens of one hundred 384-well plates can require > 10 8 À10 9 cells. If a cryopreservation step is introduced into the protocol, it is best practice to create a large working bank of cells to support the entire anticipated run of the screen. Use of culture-driven differentiation protocols requires characterization at multiple stages of differentiation to confirm that the desired cell type is produced and that batch-to-batch consistency is maintained. Key transition points in the differentiation should be confirmed by gene and/or protein expression studies. Similarly, the terminally differentiated culture should be characterized to understand the final cellular composition. Markers of contaminating cell fates as well as the desired cell fate should be assessed. Techniques such as immunocytochemistry or flow cytometry are preferred because they provide information at the level of the individual cell and are more informative than bulk techniques such as quantitative reverse transcriptase-polymerase chain reaction or western blot, in which a small population of cells can conceal heterogenous differentiation. New technologies such as scRNA-seq can provide a comprehensive, unbiased characterization of the cell types in the culture. The recent development of protocols to improve throughput and reduce cost of scRNA-seq will soon make it feasible to use these approaches for standardizing the quality control for each batch of cells (Arguel et al., 2017; Macosko et al., 2015; Rosenberg et al., 2018) . The differentiated cells ought to be further compared to the appropriate primary cell type or tissue to determine if the cells are fit for the purpose for which they are being used. At a minimum, differentiated cells should be evaluated for expression of the protein target and/or key pathways of interest should be expressed, preferably at the endogenous level of expression. If patient-specific cells are to be used, they should be carefully compared to control lines to look for obvious and subtle phenotypes that could impact interpretation of results. Functional maturity of neurons should be evaluated by electrophysiology or other measures of synaptic function. Although it intuitively can seem as if 100% purity of the target cell type should the goal, mixtures of cell types may be acceptable if the target cell type is adequately enriched, can be discriminated by an endogenous or exogenous marker, and/or the cell type mixture is reproducible. Additional optimization steps may be necessary to identify media formulations or plating conditions that accommodate multiple cell types. In some instances, it may be beneficial to generate cell types independently and combine them in a defined manner. Recently, the use of inducible transcription factor expression to drive iPSC differentiation to neural cell types has gained popularity (Busskamp et al., 2014; Cheng et al., 2017; Ho et al., 2016; Zhang et al., 2013; Zhao et al., 2015) . These protocols generally produce more homogeneous populations of cell types and more mature, terminal cell types in a compressed time frame and on a larger scale. For example, Nehme and colleagues (Nehme et al., 2018) recently demonstrated synergistic neuronal maturation through use of a combination of small-molecule and transcriptional patterning to generate induced cortical excitatory glutamatergic neurons for extensive transcriptional and functional characterization. Using single-cell RNA-seq, they confirmed the increase in homogeneous regional identity of upper layer cortical projection neurons, which was accompanied by an increase in the population of more mature, terminally differentiated neurons within the heterogeneous collection of terminal differentiation states. Microelectrode array and patch clamp electrophysiology studies confirmed AMPA and N-methyl-D-aspartate receptor-mediated synaptic transmission consistent with an excitatory glutamatergic phenotype typically found in postnatal cortical neurons. Transcription factors may be introduced via virus transduction or engineered into a safe harbor locus. Viral transduction makes it easier to induce or convert multiple iPSC lines and can enable direct conversion of non-iPSC cells such as fibroblasts, which may allow the retention of epigenetic modifications and signatures of aging (Kim et al., 2018; Mertens et al., 2015; Victor et al., 2018) . With this approach, drug selection is necessary to eliminate cells that do not take up the virus. However, cells which do not express adequate levels of the transcription factors for full differentiation may still survive drug selection and increase variability. Furthermore, variability in the sensitivity of individual cell lines to selection agents, such as puromycin, require that investigators conduct kill curves for each iPSC line to determine the optimal concentration of drug used for each iPSC line prior to viral transduction. Engineered lines take longer to produce and are more labor intensive when multiple lines must be studied; however, the resulting induction may be more uniform, as each cell starts with a single, well-characterized integration. The relative ease of inducible differentiation compared to multistep culture-driven protocols makes these protocols ideal for screening applications, and a strength of these uniform populations of neurons is their ability to provide better signalto-noise ratios for assay windows that are based on cell-autonomous phenotypes. One potential caveat is that there is a risk that transcription factor overexpression may mask subtle or developmental phenotypes.
Ensuring quality of the undifferentiated and differentiated cell cultures can create a burden in terms of cost and labor for laboratories; however, failure to ensure the quality of the cultures can render a model difficult to evaluate or reproduce. Careful planning can enable an efficient testing strategy that minimizes the number of times a sample needs to be tested or that the scope of the experiments can be adjusted. Commercial cell providers can be an alternative, readily accessible source for well-characterized and quality-controlled cells for those laboratories without the resources to engage in extensive development and validation of an in vitro differentiation protocol.
Assay Development and Validation
Best practices for assay development, whether low or high throughput, are well developed and are not substantially different for assays using iPSC-derived cells (Sittampalam et al., 2004) . Standard evaluation and optimization of conditions for cell-based assays-such as cell density per well, plating uniformity and duration of compound treatment-should be conducted. Positive and negative controls that act with a relevant mechanism of action are necessary to evaluate the dynamic range and signal-to-noise window of the assay. Signal reproducibility and signal separation between positive and negative controls over multiple plates on multiple days should be determined, as with any biochemical or enzymatic assay. Biological replicates from distinct samples that capture random biological variation should be evaluated in addition to technical replicates that capture random variation within an assay. For assays intended to screen larger numbers of compounds, a measure of assay robustness should be employed to gauge the overall quality of the assay. For example, a Z 0 calculation which captures both the signal dynamic range and the amount of data variation (Engle and Vincent, 2014; Zhang et al., 1999) or similar multiparameter composite scores in the case of high-content screens (K€ ummel et al., 2010) should be included. Automation should be employed whenever possible to enhance reproducibility. In the case of a small-molecule compound screen, the compound library choice should match both the scale at which the cells can be produced and the intended outcome of the screen (Dandapani et al., 2012) . For example, screening a relatively small ($1,280), well-annotated set of bioactive compounds such as the popular LOPAC (https://www.sigmaaldrich.com/life-science/ cell-biology/bioactive-small-molecules/lopac1280-navigator.html) can potentially identify important pathways modulating a phenotype while minimizing the overall number of cells needed. Screening a large, chemically diverse compound set will require more cells and may identify novel chemical matter for a tool compound that will aid in the understanding of the underlying biology of a protein or be the start of a drug discovery campaign.
The primary assay is only the first step in a well-designed in vitro iPSC-based screening or modeling effort. Multiple assays are required to validate any results and are necessary to further explore the robustness of the cause and effect relationship. For example, ''negative'' assay readouts in which a phenotype is lost or critical protein expression is reduced can be confounded by cellular toxicity. ''Positive'' assay readouts in which a phenotype is gained or a desired protein is increased can be confounded by compounds that broadly increase protein production or proliferation. A counter screen such as a viability assay may be necessary to control for artifacts. Orthogonal assays, which demonstrate that a compound is active in an assay system that uses a different technology or cellular platform with equivalent or greater physiological relevance, are needed to build confidence that a potential therapeutic molecule is acting via the intended mechanism (see Future Directions: Screening in Micro-physiological Systems). Additional, secondary assays that evaluate selectivity of the modularity and off-target effects should be considered. Confirmatory evaluation of initial results may include using iPSC lines of different genders, ethnic backgrounds, and mutational load. The pathway and criteria for progressing through a screening cascade should be established in advance of the primary screen to align resources (manpower, cell production, etc.) and to prioritize follow-up. Labor and material costs are always a concern for assay development. While high costs may be tolerable for low-throughput assays that enable hypothesis testing, assays that are very labor intensive and/or expensive will become prohibitive for high-throughput (>10K) screens and should minimize the reagent cost per well to < 1 US dollar to be feasible. Secondary and orthogonal assays may be more expensive per well, in line with their reduced throughput.
Where iPSC-based assays differ from traditional assays is in the level of care needed to account for the increased complexity of the biological system. As previously noted, iPSC culture and differentiation are a multistep process, and small variations at each step can accumulate to yield significantly different outcomes. Throughout the screen, cell quality control measures must be routine, rigorous, and well documented. Additional care should be used with heterogenous cell populations. In situations where only a fraction of the cells account for the phenotype of interest, the miniaturization required for higherthroughput assays can result in loss of the phenotype or assay window because of the higher well-to-well variability, which may obscure meaningful results. Protocols resulting in near-homogeneous cell populations or genetic tags such as cell-typeidentifying fluorescent proteins may be necessary to isolate or elevate the desired phenotype above the level of assay detection. Alternatively, an increased number of technical replicates or testing compounds in a dose-response format may be needed to address the increased variability.
Summary of Technical Guidance
The goal of this guidance is to assist researchers in evaluating their iPSC model during assay development. There is no objective right or wrong way to develop a model given that ''optimal'' is always dependent upon the specifics of the question being posed. Biological relevance is a continuum. Small changes, such as the use of a neuronal subtype as opposed to a generic neuron population, can have a significant effect on the relevance of the information being generated. Researchers working to understand native human biology and disease should strive to strengthen the link between the conditions they are creating in vitro and what is understood or can be measured in vivo.
As the use of iPSC-derived models increases, there is a need to ensure that the information derived from these efforts are reproducible and meaningful. In our evaluation of iPSC-derived screens, we noted a welcome increase in both the translatability and technical quality of screens from 2012 to the present (Figure 1 ). For example, in 2013, Xu and colleagues described a screen for Alzheimer's disease (AD) in wild-type iPSC-derived neurons to identify compounds that protected against exogenously added Ab 1-42 toxicity (Xu et al., 2013) . This screen captured some aspects of relevant biology, such as neurons as the target cell type and Ab 1-42 toxicity. In 2017, Kondo and colleagues described a screen for AD in iPSC-derived neurons derived from a patient carrying a PSEN1 G384A mutation (Kondo et al., 2017) . In addition to using a potentially more clinically measurable endpoint (change in Ab42/40 ratio), the authors described (1) validation of the cellular iPSC neuron phenotype by generation of an isogenic line, (2) the quality parameters associated with the assay, (3) an extensive screening follow-up culminating in the evaluation of neurons generated from additional AD, and (4) control iPSC lines thus establishing the translatability of the screen. The published data along with the supplemental information provides sufficient detail to support the quality of the screen. It is this type of high-quality data and documentation that will enable iPSC-based models to impact drug discovery in a meaningful way.
Future Directions: Screening in Microphysiological Systems
The translational potential for use of iPSC-derived models will improve proportionally with inclusion of additional elements of the in vivo disease microenvironment. Capturing more features may help resolve long-standing issues with replicating neuronal maturation, cellular and/or tissue architecture, and disease pathology. Options for improving physiologically relevant in vitro disease models include co-culture of all relevant cell types and development of 3D preparations with appropriate spatial organization of key components to improve translatability. Co-culture of Relevant Cell Types An important consideration when designing an iPSC-derived disease model is the inclusion of relevant cell types needed for modeling the impact of non-cell-autonomous effects. Glial cells represent at least half of the cells in the human brain and perform critical neuron support roles in both healthy and diseased states (Barres, 2008; Fields and Stevens-Graham, 2002) . Glial cells in co-culture with neurons can significantly alter neuronal activity and efficacy of experimental therapeutics in vitro (Burkhardt et al., 2013; Efthymiou et al., 2014; Shi et al., 2013) . Oligodendrocytes. Incorporating oligodendrocytes into cocultures will be critical for disorders of myelination. At a cellular level, multiple sclerosis symptoms stem from damaged neurons; however, the damage is the result of impaired interactions between neurons and myelin-producing oligodendrocytes. In a healthy nervous system, myelin damage cues oligodendrocyte progenitor cells (OPCs) to differentiate and restore myelination. Patients suffering from multiple sclerosis have limited capability for OPCs to differentiate and respond to myelin damage. The development of rapid protocols to induce differentiation of oligodendrocytes from human iPSC lines should enable study of patient-derived oligodendrocytes and neuron interactions that will enable testing of therapeutic approaches using in vitro myelination models (Garcia-Leó n et al., 2018). Critical to the development of these assays will be generation of 3D model systems required to enable 3D wrapping of axons and compact myelination (Kerman et al., 2015; Mei et al., 2014) . Microglia. It is becoming increasingly clear that microglia play a critical role in regulating neuronal function that goes well beyond the traditional understanding of their role in mounting proinflammatory responses during injury and disease. Microglia defend the brain against injury and pathogens, clear toxic proteins, and even promote neurogenesis. However, hyper-reactive microglia can lead to a state of chronic inflammation correlated with neurodegeneration (Colonna and Butovsky, 2017) . Microglia are key regulators of activity-dependent circuit refinement, which is regulated by the complement cascade and critical for normal development (Schafer et al., 2012) . Accumulating evidence suggests that these synaptic sculpting processes may be aberrantly activated in many disease states (Stevens and Schafer, 2018) . Furthermore, microglia interactions with astrocytes can trigger functional conversion of astrocytes from neurotrophic to neurotoxic (Liddelow et al., 2017) . Thus, while impaired neuronal viability is at the heart of neurodegeneration, future models will require co-culture with microglia to develop therapeutic approaches that aim to restore normal microglial function. The development of new protocols to reproducibly generate microglia from human iPSC lines is providing a relevant source of microglial cells which will undoubtedly become a fixture in future cell-based models of neurodevelopmental and neurodegenerative diseases (Abud et al., 2017; Douvaras et al., 2017; Haenseler et al., 2017; Muffat et al., 2016; Pandya et al., 2017) . Astrocytes. Protocols for differentiating human astrocytes from NPCs are enabling study of neuron-astrocyte interactions that contribute to disease pathology (Chandrasekaran et al., 2016; Zhang et al., 2016b) . It is well established that iPSC-derived neurons develop more mature synapses and maintain spontaneous firing activity longer when co-cultured with astrocytes (Brennand et al., 2011; Odawara et al., 2014) . Phenotypes impacted by astrocyte co-culture include neuron viability, synaptic function, and neurite outgrowth. Astrocytes also play a key role in the production of apolipoprotein E (ApoE), which is required for transport of cholesterol from astrocytes to neurons and is critical for neuronal health and function (Zhang and Liu, 2015) . In vitro models are an ideal setting to mix and match cellular components and measure the impact of specific ApoE isoforms on survival of neurons in co-culture. In growth-factor-free cultures intended to compromise neuron viability, wild-type iPSC-derived neurons homozygous for the ApoE3 allele exhibit enhanced survival when co-cultured with astrocytes also homozygous for the ε3 allele compared to ε4-derived astrocytes . Conversely, astrocytes derived from amyotrophic lateral sclerosis (ALS) mouse iPSCs can trigger cell death of heathy motor neurons in co-culture (Nagai et al., 2007; Zhang et al., 2016a) . Astrocyte genotype has also been linked to phenotypes in Huntington's disease models, in which astrocytes overexpressing the mutant huntingtin protein (HTT) produced reduced levels of cholesterol that were insufficient to support neurite outgrowth (Valenza et al., 2015) .
Recent investigation of astrocyte co-culture addressed the observation that virtually no candidate compounds aimed at preventing degeneration of dopaminergic neurons in vitro have succeeded in clinical trials. In vitro viability assays revealed that selected neuroprotective compounds provided significantly less protection of human dopaminergic neurons in co-culture with astrocytes as compared to monoculture. This was attributed to astrocyte-mediated changes in neuronal death, compound metabolism, and stress adaptations (Efremova et al., 2015) . Thus, the phenotypic state of neuron function may depend strongly on interactions with local glia to impact the accuracy of in vitro therapeutic screens. The genotype and ratio of astrocytes present in co-culture may attenuate or potentiate the effects of compounds emerging from phenotypic screens. Significantly decreased glia-neuron ratio in mice compared to humans may create discrepancies between preclinical and clinical results (Efremova et al., 2015) . The inclusion of wild-type rodent astrocytes to support patient-derived iPSC neurons has the potential to mask important human neuronal phenotypes (Kelley and Rowitch, 2016) . Future model systems will need to include disease-relevant human astrocytes in disease-relevant proportions to improve the translatability of assays.
Modeling of 3D Tissues
Building screening platforms in 3D will achieve a more biologically relevant physical organization of cells by better replicating in vivo cell-cell and cell-matrix interactions (Skardal et al., 2016) . 3D culture promotes neuronal maturity and, for example, expression of mature isoforms of the tau protein, an important consideration for platforms modeling AD and other tauopathies (Choi et al., 2014) . iPSCs differentiated in 3D exhibit more robust neural and glial differentiation, accelerated deposition of amyloid-beta, and enhanced responsiveness to inhibitors targeting tau phosphorylation compared to 2D differentiation (Choi et al., 2016) . Organoids. iPSCs patterned to neuroectoderm possess the ability to self-assemble into spheroids, where spontaneous differentiation leads to physiological, laminar organization of neurons and glia in a scalable format. In addition to containing the variety of differentiated cell types found in in vivo tissues, organoids exhibit more physiologically relevant cell organization, cell signaling, and cell-matrix interactions than standard 2D culture systems (Hynds and Giangreco, 2013) . Cerebral organoids can be generated from patient iPSCs by embedding iPSCderived neuroectodermal tissue in droplets consisting of a 3D matrix scaffold (Lancaster and Knoblich, 2014) . Tissues can be maintained for at least 10 months in spinning bioreactors to enhance nutrient diffusion, where they can grow up to 4 mm in diameter (Lancaster et al., 2013) . Gross morphological analysis of organoids grown using this method revealed distinct lamina and regional specification confirmed by localized immunohistochemical staining for forebrain, midbrain, and hindbrain markers as well as by sub-regional markers. Cerebral organoids also show expected functional neural activity as evidenced by measured calcium oscillations, glutamate receptor activity, and axon branching. The first example of an organoid disease model was an iPSC-derived organoid model of microencephaly. Organoids generated from cells of a microencephaly patient showed premature neural differentiation and smaller neural tissues compared to control organoids, reflective of observations in vivo. By capturing specific defects in the neural expansion process, these organoids provided a more translatable model of human microencephaly than mouse models, which do not adequately reflect the severity of the disorder in humans (Lancaster et al., 2013) . Given the 3D architecture, organoids may be particularly suited for technologies such as seqFISH that capture both spatial organization and gene expression (Shah et al., 2016) .
While iPSC-based organoids are being applied to model neuronal disease pathology, to date, the variability among individual organoids has made it difficult to adopt as a primary screening platform in phenotypic screens (Camp et al., 2015; Dang et al., 2016; Qian et al., 2016) . The use of organoids as secondary screens following hit identification in cell lines has begun to show promise. Zika virus (ZIKV) infection causes congenital defects that lead to microencephaly, and infected organoids provided an effective 3D model of early brain development on which to evaluate therapies. A recent screen first identified small-molecule inhibitors of ZIKV infection in glioblastoma cells, NPC, and astrocytes. A follow-up study of selected hit compounds was then performed using forebrain-specific organoids to evaluate compound cytotoxicity and ability of the compounds to rescue cells from ZIKV infection (Xu et al., 2016a) . Another screen for ZIKV inhibitors also applied organoids in a follow-up to the primary screen (Zhou et al., 2017) . The development of protocols that improve the uniformity and reproducibility of individual organoids through systematic optimization of media and growth conditions will likely enable the automation and industrialization of these microtissues for drug screening within the next few years. However, it will still require a significant reduction in cost of production of organoids to make it feasible to run primary screens with these tissues. Microfluidics and Bioprinting. Restriction of cells to distinct regions of 3D space can be accomplished by layering hydrogels within microfluidic chips or by 3D bioprinting. Hydrogels polymerized in situ can be layered to recapitulate tissue architecture and promote specific cell-cell interactions that produce assay systems for monitoring neuronal migration and maturation phenotypes. Using this approach, Zhang and colleagues (Zhang et al., 2016b) revealed novel developmental migration phenotypes for NPCs co-cultured with neurons or astrocytes in adjacent hydrogel layers. The ability to vary composition and mechanical properties of layered matrices results in a tunable platform to mimic brain tissue at a variety of developmental and disease states while allowing for high-resolution imaging of human cell-migratory behavior in 3D (Zhang et al., 2016b) . A recent example of the power of this approach comes from studies by Park and colleagues (Park et al., 2018) who showed that, in a 3D microfluidic model of AD comprised of co-cultures of human iPSC-derived neurons expressing high levels of pathogenic Ab and astrocytes, microglial migration and recruitment were increased over control neurons and led to increased neuronal and astrocyte loss by treatment with interferon g. The inclusion of microglia in the model highlights the growing realization that components of the immune system are often critical contributors to the expression of a phenotype. It is likely that, as 3D cellular models become more sophisticated, inclusion of components of the immune system will become more common.
Layered hydrogels combined with microfluidics also enables simulation of physiological microenvironments needed to investigate disease phenotypes of the blood-brain barrier (BBB), which functions to regulate cross-talk between brain tissue and systemic circulation. Disruption of the BBB plays a role in ischemia and brain injury as well as MS, where autoimmune responses trigger BBB disruption and entry of activated leukocytes that initiate myelin breakdown (Palmer, 2013; Rosenberg, 2012) . Physiologically relevant BBB models provide a promising foundation for future phenotypic approaches that evaluate and repair BBB breakdown in neurological disorders. Existing protocols allow detection of changes in BBB permeability and the corresponding neuronal responses, which can facilitate discovery of compounds that rescue neuron damage by tightening the BBB or restricting leukocyte transmigration (Adriani et al., 2017; Brown et al., 2015) . New chip design and fabrication will be needed integrate automation and increase throughput to support therapeutic screens for highly integrated disease phenotypes. To this end, Wevers and colleagues (Wevers et al., 2018) recently described a high-throughput, plate-based, perfused BBB on a chip that incorporates brain endothelial cells, astrocytes, and pericytes to create a platform with sufficient barrier function to study the transcytosis of large molecules and support drug discovery efforts. Although they utilize SV40 large T-antigen immortalized primary human cell lines, their work highlights the beneficial effects of perfusion and co-culture in producing greater barrier integrity into a system that allows for the measurement of 40 or 96 samples per experiment and can readily be adapted for use with iPSC-derived cells.
Protocols to develop iPSC-derived spinal motor neurons are among the most robust and well-developed in the literature, making modeling of neuromuscular disorders an attractive phenotypic screening preparation (Davis-Dusenbery et al., 2014; Makhortova et al., 2011; Son et al., 2011; Wainger et al., 2014) . However, motor neurons grown on a flat surface, innervating only other motor neurons, will not faithfully replicate the characteristic features needed to model disease. By contrast, co-culture of motor neurons and skeletal muscle cells has been used to mimic the remote innervation of muscle tissue by the spinal cord in a novel microfluidic compartmentalized model of the neuromuscular junction (Uzel et al., 2016) . This platform contains spheroids of mouse embryonic stem-cellderived motor neurons suspended in a hydrogel that allows axons to extend through a second hydrogel chamber to innervate a strip of skeletal muscle. The platform design includes a force sensor within the skeletal muscle strip and optical control of motor neuron excitation. Critically, these features enable quantification of relevant phenotypic readouts (Sakar et al., 2012) . Preliminary evaluation of this model demonstrated the potential to recapitulate delayed muscle stimulation by ALS motor neurons, which show increased vulnerability to glutamate excitotoxicity (Foran and Trotti, 2009 ). Failure of motor units is at the root of disorders such as ALS and Duchenne muscular dystrophy; incorporation of 3D cell interactions and anatomical cell patterning into screening platforms will improve the translatability of resulting screens.
The advent of 3D cellular bioprinting technology will take cell patterning specificity to a promising new level, giving researchers seemingly limitless design input. Bioprinting requires both an engineering approach to bottom-up microenvironment design and a comprehensive knowledge of relevant components of the disease biology. Current bioprinting technologies are compatible with most standard matrix proteins, and new matrices are designed to improve molecule delivery and tune mechanical stress in 3D (Murphy and Atala, 2014) . Screening platforms can be bio-printed directly in a Petri dish or used in conjunction with microfluidic principles to design truly complex organ models that replicate drug delivery in vivo (Duan et al., 2013; Yang et al., 2017) . To fulfill the future promise of an in vitro screen as a reliable tool for precision medicine, the field will need to integrate these tools into future screening platforms.
Remaining Challenges in Developing iPSC-Derived Models iPSC-derived models hold the potential to trigger a paradigm shift in the neurosciences as the quality and reproducibility of human in vitro models continue to improve. The barriers that limit the widespread adoption of best practices include the expense associated with proper characterization of cells and the difficulty associated with distinguishing high-quality iPSC lines from poorquality lines. Investigators looking for high-quality lines can struggle to identify and access iPSC lines which are well suited to model development. The field would benefit from identification of a panel of a genetically diverse, disease-relevant iPSC lines that have documented patient consent for widespread use, quality control data demonstrating genomic integrity, and standardized scRNA-seq data to help researchers select appropriate lines (Kolodziejczyk et al., 2015; Wen and Tang, 2016) .
New protocols that reduce the expense and complexity of differentiating brain cell types from iPSC lines by using engineered, inducible transcription-factor-driven protocols will make the accessibility of screening compatible human neuron systems available to an even broader range of neurobiology investigators, many of whom do not have a formal stem cell biology background. As the field transitions from an early to a more mature phase, it will be critical for the field to hold itself to the highest standards of quality and translatability to ensure the integrity of these studies. Enforcing best practices may take some extra effort, but it will be necessary to translate the promise of stem-cell-based disease models into new therapeutic molecules that benefit patients.
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